Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OmniSonics Medical Technologies has enrolled its first patient in the prospective, multi-center US Sonic II Registry study to evaluate the company's OmniWave Endovascular System in patients undergoing percutaneous mechanical thrombectomy for acute limb ischemia.
Subscribe to our email newsletter
All patients enrolled in the Sonic II Registry are scheduled for follow-up at 30 days, six months, and one year following the OmniWave procedure. The first patient was enrolled at the Midwest Institute for Minimally Invasive Therapies (MIMIT) in Chicago.
Richard Ganz, president and CEO of OmniSonics, said: “The initiation of the Sonic II Registry is an important strategic development in OmniSonics’s continuation of a strong clinical program to support the OmniWave System as a therapy for treating patients with acute limb ischemia (ALI).”